<Summary id="CDR0000062764" LegacyPDQID=""><SummaryMetaData><SummaryType>Prevention</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Skin cancer prevention strategies include avoiding risk factors such as ultraviolet radiation, and increasing protective factors. Get detailed information about factors that influence the risk of skin cancer and interventions aimed at preventing it in this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/skin/hp/skin-prevention-pdq">Skin Cancer (PDQ®): Prevention</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/skin/patient/skin-prevention-pdq">Skin Cancer (PDQ®): Prevention</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028536">PDQ Screening and Prevention Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038781">skin cancer</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000041588">cancer prevention</TermRef></MainTopics><SummaryAbstract><Para id="_202">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about skin cancer prevention. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_203">This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>cancer prevention</SummaryKeyWord><SummaryKeyWord>skin cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Skin Cancer Prevention (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Skin Cancer Prevention (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Skin Cancer Prevention</AltTitle><SummarySection id="_146"><Title>Who Is at Risk?</Title><Para id="_147">Individuals who have light-hair and -eye color, freckles, and who sunburn easily are particularly susceptible to developing skin cancer.<Reference refidx="1"/> There are two primary types of skin cancer, keratinocyte carcinoma (including basal cell carcinoma and squamous cell carcinoma [SCC]) and melanoma. Observational and analytic epidemiological studies have consistently shown that increased cumulative sun exposure is a risk factor for keratinocyte carcinoma.<Reference refidx="1"/><Reference refidx="2"/> Melanoma risk correlates with common and atypical nevi.<Reference refidx="3"/> Some studies suggest that there may be an interplay between genetic phenotype and sun exposure and that there may be two pathways to melanoma development.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_294">Organ transplant recipients taking immunosuppressive drugs are at an elevated risk of developing skin cancer, particularly SCC.<Reference refidx="8"/><Reference refidx="9"/> Arsenic exposure also increases the risk of keratinocytic cancers <Reference refidx="10"/> and melanoma.<Reference refidx="11"/></Para><ReferenceSection><Citation idx="1" PMID="1435901" MedlineID="93063090">Preston DS, Stern RS: Nonmelanoma cancers of the skin. N Engl J Med 327 (23): 1649-62, 1992.</Citation><Citation idx="2" PMID="9663594" MedlineID="98326727">English DR, Armstrong BK, Kricker A, et al.: Case-control study of sun exposure and squamous cell carcinoma of the skin. Int J Cancer 77 (3): 347-53, 1998.</Citation><Citation idx="3" PMID="15617989">Gandini S, Sera F, Cattaruzza MS, et al.: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41 (1): 28-44, 2005.</Citation><Citation idx="4" PMID="28478931">Armstrong BK, Cust AE: Sun exposure and skin cancer, and the puzzle of cutaneous melanoma: A perspective on Fears et al. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. American Journal of Epidemiology 1977; 105: 420-427. Cancer Epidemiol 48: 147-156, 2017.</Citation><Citation idx="5" PMID="31747047">Olsen CM, Pandeya N, Law MH, et al.: Does polygenic risk influence associations between sun exposure and melanoma? A prospective cohort analysis. Br J Dermatol 183 (2): 303-310, 2020.</Citation><Citation idx="6" PMID="31366280">Davis LE, Shalin SC, Tackett AJ: Current state of melanoma diagnosis and treatment. Cancer Biol Ther 20 (11): 1366-1379, 2019.</Citation><Citation idx="7" PMID="26563358">Gershenwald JE, Guy GP: Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. J Natl Cancer Inst 108 (1): , 2016.</Citation><Citation idx="8" PMID="28746700">Ascha M, Ascha MS, Tanenbaum J, et al.: Risk Factors for Melanoma in Renal Transplant Recipients. JAMA Dermatol 153 (11): 1130-1136, 2017.</Citation><Citation idx="9" PMID="35803453">Rollan MP, Cabrera R, Schwartz RA: Current knowledge of immunosuppression as a risk factor for skin cancer development. Crit Rev Oncol Hematol 177: 103754, 2022.</Citation><Citation idx="10" PMID="5644201">Tseng WP, Chu HM, How SW, et al.: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40 (3): 453-63, 1968.</Citation><Citation idx="11" PMID="15383412">Beane Freeman LE, Dennis LK, Lynch CF, et al.: Toenail arsenic content and cutaneous melanoma in Iowa. Am J Epidemiol 160 (7): 679-87, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_213"><Title>Overview</Title><Para id="_2">Note: The Overview section summarizes the published evidence on this topic. The rest of the summary describes the evidence in more detail.</Para><Para id="_283">Other PDQ summaries containing information related to skin cancer prevention include the following:</Para><ItemizedList id="_285" Style="bullet">
     <ListItem><SummaryRef href="CDR0000062750" url="/types/skin/hp/skin-screening-pdq">Skin Cancer Screening</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062909" url="/types/skin/hp/skin-treatment-pdq">Skin Cancer
Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000552637" url="/types/skin/hp/skin-genetics-pdq">Genetics of Skin Cancer</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000304747" url="/publications/pdq/levels-evidence/screening-prevention">Levels of Evidence for Cancer Screening and Prevention Studies</SummaryRef></ListItem></ItemizedList><SummarySection id="_182"><Title>Factors Associated With an Increased Risk of Keratinocyte Carcinoma (Basal Cell Carcinoma, Squamous Cell Carcinoma)</Title><SummarySection id="_218"><Title>Fair skin</Title><Para id="_219">Based on solid evidence, individuals with fair skin types (light or pale skin, light-hair and -eye color, freckles, or those who burn easily) are associated with an increased risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).</Para><Para id="_220"><Strong>Magnitude of Effect</Strong>: Substantial, depending on the amount of exposure.</Para><ItemizedList id="_221" Style="simple">
     <ListItem><Strong>Study Design</Strong>: Observational studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Good.</ListItem><ListItem><Strong>External Validity</Strong>: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_183"><Title>Sun and UV radiation exposure</Title><Para id="_184">Based on solid evidence, sun and UV radiation exposure are associated with an increased risk of SCC and BCC.</Para><Para id="_185"><Strong>Magnitude of Effect</Strong>: Substantial, depending on the amount of exposure.</Para><ItemizedList id="_150" Style="simple"><ListItem><Strong>Study Design</Strong>: Observational studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Good.</ListItem><ListItem><Strong>External Validity</Strong>: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_295"><Title>Immunosuppression</Title><Para id="_296">Based on solid evidence, immunosuppression after organ transplant is associated with an increased risk of SCC and BCC.</Para><Para id="_297"><Strong>Magnitude of Effect</Strong>: Substantial, although not consistently quantitated.</Para><ItemizedList id="_298" Style="simple">
     <ListItem><Strong>Study Design</Strong>: Observational studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Good.</ListItem><ListItem><Strong>External Validity</Strong>: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_311"><Title>Arsenic exposure</Title><Para id="_300">Based on fair evidence, arsenic exposure is associated with an increased risk of keratinocyte carcinoma.</Para><Para id="_301"><Strong>Magnitude of Effect</Strong>: Arsenic exposure is associated with keratinocyte carcinoma.</Para><ItemizedList id="_302" Style="simple">
     <ListItem><Strong>Study Design</Strong>: One case-control study.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Fair.</ListItem><ListItem><Strong>External Validity</Strong>: Fair.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_186"><Title>Factors Associated With an Increased Risk of Melanoma</Title><SummarySection id="_187"><Title>Sun and UV radiation exposure</Title><Para id="_188">Based on fair evidence, intermittent acute sun exposure leading to sunburn is associated with an increased risk of melanoma.</Para><Para id="_189"><Strong>Magnitude of Effect</Strong>: Unknown.</Para><ItemizedList id="_163" Style="simple"><ListItem><Strong>Study Design</Strong>: Observational studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Fair.</ListItem><ListItem><Strong>Consistency</Strong>: Fair.</ListItem><ListItem><Strong>External Validity</Strong>: Poor.</ListItem></ItemizedList></SummarySection><SummarySection id="_299"><Title>Arsenic exposure</Title><Para id="_312">Based on fair evidence, arsenic exposure is associated with an increased risk of melanoma.</Para><Para id="_313"><Strong>Magnitude of Effect</Strong>: Arsenic exposure is associated with double the incidence of melanoma.</Para><ItemizedList id="_314" Style="simple">
     <ListItem><Strong>Study Design</Strong>: One case-control study.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Fair.</ListItem><ListItem><Strong>External Validity</Strong>: Fair.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_239"><Title>Interventions for Skin Cancer Prevention With Adequate Evidence</Title><SummarySection id="_240"><Title>Treatment of sun-damaged skin to prevent skin cancer: Benefits</Title><Para id="_241">There is one well designed randomized controlled trial (RCT) that demonstrated the use of topical fluorouracil on sun-damaged skin prevents additional actinic keratoses and SCC requiring surgery.<Reference refidx="1"/></Para><Para id="_242"><Strong>Magnitude of Effect</Strong>: Moderate net benefit in preventing SCC requiring surgery.</Para><ItemizedList id="_243" Style="simple">
     <ListItem><Strong>Study Design</Strong>: RCT.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: N/A (single study).</ListItem><ListItem><Strong>External Validity</Strong>: Fair.</ListItem></ItemizedList></SummarySection><SummarySection id="_244"><Title>Treatment of sun-damaged skin to prevent skin cancer: Harms</Title><Para id="_245">The primary side effect is local erythema, irritation, and crusting.</Para></SummarySection></SummarySection><SummarySection id="_151"><Title>Interventions for Skin Cancer Prevention With Inadequate Evidence</Title><SummarySection id="_222"><Title>Behavior counseling to change sun-protection practices: Benefits</Title><Para id="_223">Evidence from 21 RCTs demonstrated that behavior counseling for children and families and for adults improves sun protective behaviors. These trials showed an inconsistent effect on reducing sunburns and do not provide direct evidence on reduction of SCC, BCC, or melanoma.<Reference refidx="2"/></Para><Para id="_226"><Strong>Magnitude of Benefit</Strong>: Moderate net benefit for improving sun protective behaviors, but there is inadequate direct evidence to determine the impact on the development of skin cancer.</Para><ItemizedList id="_228" Style="simple">
     <ListItem><Strong>Study Design</Strong>: Systematic review including 21 RCTs.</ListItem><ListItem><Strong>Internal Validity</Strong>: Good.</ListItem><ListItem><Strong>Consistency</Strong>: Good for behaviors. Poor for sunburns.</ListItem><ListItem><Strong>External Validity</Strong>: Good.</ListItem></ItemizedList></SummarySection><SummarySection id="_224"><Title>Behavior counseling to change sun-protection practices: Harms</Title><Para id="_225">Avoiding sun exposure can result in harms, such as mood disorders, sleep disturbances, elevated blood pressure, and impaired vitamin D metabolism, which is associated with increased incidence of colon, ovary, and breast cancers, and multiple myeloma.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_229"><Title>Topical treatments to prevent skin cancer—sunscreen: Benefits</Title><Para id="_231">Sunscreen has been shown to prevent sunburns and actinic keratoses. RCTs showed inconsistent benefit in preventing SCC and showed no benefit in preventing melanoma.</Para><Para id="_232"><Strong>Magnitude of Effect</Strong>: Inadequate evidence to assess magnitude of effect for sunscreen.</Para><ItemizedList id="_236" Style="simple">
     <ListItem><Strong>Study Design</Strong>: RCTs and observational cohort studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Poor.</ListItem><ListItem><Strong>Consistency</Strong>: Inconsistent.</ListItem><ListItem><Strong>External Validity</Strong>: Poor.</ListItem></ItemizedList></SummarySection><SummarySection id="_233"><Title>Topical treatments to prevent skin cancer—sunscreen: Harms</Title><Para id="_235">Harms of sunscreen for the user are mild and mainly include skin allergic reactions. Because sunscreen use prevents sunburns, it may encourage more sun exposure to fair skinned people at risk of developing skin cancer.</Para></SummarySection><SummarySection id="_291"><Title>Systemic treatments to prevent skin cancer (nonsteroidal anti-inflammatory drugs [NSAIDs], nicotinamide, isotretinoin, selenium, beta carotene, alpha-difluoromethylornithine [DFMO]): Benefits</Title><Para id="_286">There is no evidence showing that NSAIDs and nicotinamide prevent SCC. RCTs found no benefit in preventing SCC, BCC, or melanoma for topical or oral retinoids, selenium, and beta carotene. One RCT showed a slight reduction in BCC for DFMO, but no change in SCC or melanoma.</Para><Para id="_287"><Strong>Magnitude of Effect</Strong>: Inadequate evidence to assess magnitude of effect for topical retinoids, and nicotinamide. Harms likely outweigh potential benefits for NSAIDs, oral retinoids, beta carotene, and DFMO.</Para><ItemizedList id="_288" Style="simple">
     <ListItem><Strong>Study Design</Strong>: RCTs and observational cohort studies.</ListItem><ListItem><Strong>Internal Validity</Strong>: Poor.</ListItem><ListItem><Strong>Consistency</Strong>: Inconsistent.</ListItem><ListItem><Strong>External Validity</Strong>: Poor.</ListItem></ItemizedList></SummarySection><SummarySection id="_289"><Title>Systemic treatments to prevent skin cancer (NSAIDs, nicotinamide, isotretinoin, selenium, beta carotene, DFMO): Harms</Title><Para id="_290">NSAIDs are associated with adverse cardiovascular effects, gastrointestinal bleeding, and kidney damage. Oral retinoids are hepatotoxic and cause hypertriglyceridemia. In RCTs, beta carotene is associated with an increased risk of lung cancer incidence and mortality in smokers. Isotretinoin has dose-related skin toxicity. Patients discontinue DFMO at high rates because of hearing loss. </Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="29299592">Weinstock MA, Thwin SS, Siegel JA, et al.: Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol 154 (2): 167-174, 2018.</Citation><Citation idx="2" PMID="29558557">Henrikson NB, Morrison CC, Blasi PR, et al.: Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319 (11): 1143-1157, 2018.</Citation><Citation idx="3" PMID="18414615">Mead MN: Benefits of sunlight: a bright spot for human health. Environ Health Perspect 116 (4): A160-7, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_107"><Title>Incidence and Mortality of Skin Cancer</Title><Para id="_108">There are two main types of skin cancer:</Para><ItemizedList id="_180" Style="bullet"><ListItem>Keratinocyte carcinoma.<ItemizedList id="_214" Style="dash">
     <ListItem>Basal cell carcinoma (BCC).</ListItem><ListItem>Squamous cell carcinoma (SCC).</ListItem></ItemizedList></ListItem><ListItem>Melanoma.</ListItem></ItemizedList><Para id="_181">BCC  and SCC are the most common forms of skin cancer but have substantially better prognoses than the less common, generally more aggressive, melanoma.</Para><Para id="_109">Keratinocyte carcinomas are the most commonly occurring cancer in the United States, but exact incidence figures are unavailable because cases are not required to be reported to cancer registries.  Incidence rates appear to have been increasing for a number of years,<Reference refidx="1"/> in part due to increased screening and biopsy of skin lesions. Based on an extrapolation of Medicare fee-for-service data to the U.S. population, about 3 million individuals were estimated to have been diagnosed with keratinocyte carcinomas in 2012,<Reference refidx="1"/><Reference refidx="2"/> exceeding all other cancer cases (approximately 2 million) estimated by the American Cancer Society in 2025.<Reference refidx="1"/></Para><Para id="_110">Melanoma cases are reported to U.S. cancer registries, so data are available. In 2025, an estimated 104,960 individuals in the United States will be diagnosed with melanoma and approximately 8,430  will die of the disease.<Reference refidx="1"/> While only 2% of skin cancers are melanomas, melanoma causes more than 80% of deaths from skin cancer.<Reference refidx="3"/></Para><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. <ExternalRef xref="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf">Available online</ExternalRef>. Last accessed January 16, 2025.</Citation><Citation idx="2" PMID="25928283">Rogers HW, Weinstock MA, Feldman SR, et al.: Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol 151 (10): 1081-6, 2015.</Citation><Citation idx="3" PMID="1863078">Weinstock MA, Bogaars HA, Ashley M, et al.: Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 127 (8): 1194-7, 1991.</Citation></ReferenceSection></SummarySection><SummarySection id="_303"><Title>Accuracy of Making a Clinical Diagnosis of Melanoma</Title><Para id="_304">Observer variability among physicians has been noted in the evaluation of skin lesions and subsequent biopsy specimens. A systematic review of 32 studies that compared the accuracy of dermatologists and primary care physicians in making a clinical diagnosis of melanoma concluded that there was no statistically significant difference in accuracy.  However, the results were inconclusive, owing to small sample sizes and study design weaknesses.<Reference refidx="1"/> Subsequent studies have noted a higher accuracy for dermatologists in the diagnosis of melanocytic lesions,<Reference refidx="2"/><Reference refidx="3"/> yet there is a shortage of dermatologists to meet the demands of population-level screening.</Para><Para id="_305">A study of 187 pathologists in the United States found that cases of moderately dysplastic nevi to early-stage invasive melanoma had less than 50% agreement with a reference diagnosis defined by consensus of experienced pathologists.<Reference refidx="4"/> At a U.S. population level, it is estimated that 82.8% (95% confidence interval, 81.0%–84.5%) of melanocytic skin biopsy diagnoses would be verified if they were reviewed by a consensus reference panel of experienced pathologists.<Reference refidx="4"/> In addition, differentiating between benign and malignant melanocytic tumors during histological examinations of biopsy specimens has been shown to be  inconsistent, even in the hands of experienced dermatopathologists.<Reference refidx="5"/><Reference refidx="6"/> This variability in the diagnosis of melanocytic lesions undermines the results of studies that examine screening effectiveness and also may undermine the effectiveness of any screening intervention. Furthermore, this finding suggests that requesting a second opinion regarding the pathology of biopsy specimens may be important.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> A standard approach to the classification of melanocytic skin lesions by pathologists may also reduce confusion and improve communication between clinicians.<Reference refidx="4"/><Reference refidx="6"/><Reference refidx="8"/><Reference refidx="9"/></Para><ReferenceSection><Citation idx="1" PMID="11735713">Chen SC, Bravata DM, Weil E, et al.: A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. Arch Dermatol 137 (12): 1627-34, 2001.</Citation><Citation idx="2" PMID="16808765">Chen SC, Pennie ML, Kolm P, et al.: Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med 21 (7): 678-82, 2006.</Citation><Citation idx="3" PMID="22971304">Corbo MD, Wismer J: Agreement between dermatologists and primary care practitioners in the diagnosis of malignant melanoma: review of the literature. J Cutan Med Surg 16 (5): 306-10, 2012 Sep-Oct.</Citation><Citation idx="4" PMID="28659278">Elmore JG, Barnhill RL, Elder DE, et al.: Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 357: j2813, 2017.</Citation><Citation idx="5" PMID="8666360" MedlineID="96251214">Farmer ER, Gonin R, Hanna MP: Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 27 (6): 528-31, 1996.</Citation><Citation idx="6" PMID="27189823">Lott JP, Elmore JG, Zhao GA, et al.: Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group. J Am Acad Dermatol 75 (2): 356-63, 2016.</Citation><Citation idx="7" PMID="31603483">Piepkorn MW, Longton GM, Reisch LM, et al.: Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions. JAMA Netw Open 2 (10): e1912597, 2019.</Citation><Citation idx="8" PMID="24176521">Piepkorn MW, Barnhill RL, Elder DE, et al.: The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. J Am Acad Dermatol 70 (1): 131-41, 2014.</Citation><Citation idx="9" PMID="32935869">Radick AC, Reisch LM, Shucard HL, et al.: Terminology for melanocytic skin lesions and the MPATH-Dx classification schema: A survey of dermatopathologists. J Cutan Pathol 48 (6): 733-738, 2021.</Citation></ReferenceSection></SummarySection><SummarySection id="_172"><Title>Risk Factors for Skin Cancer</Title><Para id="_112">Epidemiological evidence
suggests that exposure to UV radiation and the sensitivity of an
individual’s skin to UV radiation are the main risk factors for skin cancer, although
the type of exposure (high-intensity and short-duration vs. chronic exposure) and the pattern
of exposure (continuous vs. intermittent) may differ among the  two main skin cancer types.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_306">The immune system plays a role in the pathogenesis of skin cancer: organ transplant recipients taking immunosuppressive drugs are at an elevated risk of skin cancer, both squamous cell carcinoma (SCC) and melanoma.<Reference refidx="4"/>  Arsenic exposure also increases the risk of cutaneous SCC.<Reference refidx="4"/></Para><Para id="_113">The visible evidence of susceptibility to skin cancer (skin type and precancerous
lesions), presence of sun-induced skin damage (sunburn and solar keratoses), and increased number of nevi and atypical nevi are associated with an increased risk of melanoma.<Reference refidx="5"/><Reference refidx="6"/></Para><SummarySection id="_173"><Title>Factors Associated With Increased Risk of Keratinocyte Carcinoma </Title><SummarySection id="_114"><Title>UV radiation exposure</Title><Para id="_115">Most evidence about UV radiation exposure and the prevention of skin cancer
comes from observational and analytic epidemiological studies.  Such studies have consistently shown that
increased cumulative sun exposure is a risk factor for keratinocyte carcinomas.<Reference refidx="2"/><Reference refidx="3"/>  Individuals whose skin tans poorly or burns easily after sun
exposure are particularly susceptible.<Reference refidx="2"/></Para></SummarySection><SummarySection id="_247"><Title>Actinic keratoses</Title><Para id="_248">It is generally felt that one-half or more of SCCs  arise from actinic keratoses.  However, nearly one-half of SCCs occur in clinically normal skin.<Reference refidx="7"/>   A longitudinal study has shown that the progression rate from actinic keratoses to SCC is about 0.075% to 0.096% per year, or less than 1 case in 1,000 per year.<Reference refidx="7"/>   Moreover, in a population-based longitudinal study, there was an approximately 26% spontaneous regression rate of actinic keratoses within 1 year of a screening examination.<Reference refidx="8"/></Para></SummarySection></SummarySection><SummarySection id="_176"><Title>Factors Associated With an Increased Risk of Melanoma</Title><SummarySection id="_118"><Title>UV radiation exposure</Title><Para id="_119">The relationship between UV radiation exposure and cutaneous melanoma is less
clear than the relationship between UV exposure and keratinocyte carcinoma.  In the case of melanoma,  it seems that   intermittent acute sun
exposure leading to sunburn is more important than cumulative sun exposure;<Reference refidx="9"/> such exposures during childhood or
adolescence may be particularly important.<Reference refidx="1"/></Para><Para id="_282">Multiple case control studies have also documented the association between sun exposure and melanoma. Total sun exposure in childhood is associated with an increased risk of melanoma (odds ratio, 1.81–4.4) as is recreational sun exposure during childhood and adulthood, while occupational sun exposure may be associated with a decreased risk of melanoma.<Reference refidx="10"/><Reference refidx="11"/>
Fair skin that sunburns easily has a twofold risk of melanoma compared with skin phenotypes that never burn. Natural red and blond hair and natural blond hair also confers a twofold to fourfold increased risk of melanoma.<Reference refidx="12"/></Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="1805813" MedlineID="91270330">Koh HK: Cutaneous melanoma. N Engl J Med 325 (3): 171-82, 1991.</Citation><Citation idx="2" PMID="1435901" MedlineID="93063090">Preston DS, Stern RS: Nonmelanoma cancers of the skin. N Engl J Med 327 (23): 1649-62, 1992.</Citation><Citation idx="3" PMID="9663594" MedlineID="98326727">English DR, Armstrong BK, Kricker A, et al.: Case-control study of sun exposure and squamous cell carcinoma of the skin. Int J Cancer 77 (3): 347-53, 1998.</Citation><Citation idx="4" PMID="15383412">Beane Freeman LE, Dennis LK, Lynch CF, et al.: Toenail arsenic content and cutaneous melanoma in Iowa. Am J Epidemiol 160 (7): 679-87, 2004.</Citation><Citation idx="5" PMID="15617989">Gandini S, Sera F, Cattaruzza MS, et al.: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41 (1): 28-44, 2005.</Citation><Citation idx="6" PMID="15894679">Cho E, Rosner BA, Colditz GA: Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 14 (5): 1241-4, 2005.</Citation><Citation idx="7" PMID="2895318">Marks R, Rennie G, Selwood TS: Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1 (8589): 795-7, 1988.</Citation><Citation idx="8" PMID="3801305">Marks R, Foley P, Goodman G, et al.: Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 115 (6): 649-55, 1986.</Citation><Citation idx="9" PMID="15617990">Gandini S, Sera F, Cattaruzza MS, et al.: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41 (1): 45-60, 2005.</Citation><Citation idx="10">Lin JS, Eder M, Weinmann S, et al.: Behavioral Counseling to Prevent Skin Cancer: Systematic Evidence Review to Update the 2003 U.S. Preventive Services Task Force Recommendation. Agency for Healthcare Research and Quality, 2011. Report No.: 11-05152-EF-1. <ExternalRef xref="https://pubmed.ncbi.nlm.nih.gov/21542545/">Also available online</ExternalRef>. Last accessed April 8, 2025.</Citation><Citation idx="11" PMID="29558557">Henrikson NB, Morrison CC, Blasi PR, et al.: Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319 (11): 1143-1157, 2018.</Citation><Citation idx="12" PMID="16125929">Gandini S, Sera F, Cattaruzza MS, et al.: Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41 (14): 2040-59, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_267"><Title>Interventions for Skin Cancer Prevention With Adequate Evidence of Benefit</Title><SummarySection id="_268"><Title>Treatment of Sun-Damaged Skin to Prevent Skin Cancer</Title><SummarySection id="_269"><Title>Topical fluorouracil</Title><Para id="_270">Daily application of topical fluorouracil for up to 4 weeks onto actinic keratosis has been shown to reduce the development of new actinic keratoses.<Reference refidx="1"/><Reference refidx="2"/>   A randomized controlled trial included 932 veterans with sun-damaged skin (two or more keratinocyte carcinomas in the 5 years before enrollment). Participants were randomly assigned to a 2- to 4-week single course of 5% topical fluorouracil or vehicle control cream. The fluorouracil group had fewer actinic keratosis cases when compared with the control group at 6 months (3.0 vs. 8.1; <Emphasis>P</Emphasis> &lt; .001) and for the overall study duration (<Emphasis>P</Emphasis> &lt; .001). Topical fluorouracil also reduced the risk of squamous cell carcinoma (SCC) requiring surgery at those sites for 1 year, but no effect was seen on basal cell carcinoma (BCC) in year 1 or on SCC or BCC over 4 years. Erythema, crusting, and irritation were reported by 82% of participants, with 40% reporting symptoms as severe. However, at study completion, 87% reported a willingness to repeat the treatment if needed.<Reference refidx="1"/>     </Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="29299592">Weinstock MA, Thwin SS, Siegel JA, et al.: Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol 154 (2): 167-174, 2018.</Citation><Citation idx="2" PMID="30895944">Rosenberg AR, Tabacchi M, Ngo KH, et al.: Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight 4 (6): , 2019.</Citation></ReferenceSection></SummarySection><SummarySection id="_174"><Title>Interventions for Skin Cancer Prevention With Inadequate Evidence of Benefit</Title><SummarySection id="_129"><Title>Behavioral Interventions to Change Sun-Protective Practices</Title><Para id="_130">The U.S. Preventive Services Task Force (USPSTF) commissioned a systematic review of primary care behavioral counseling interventions for skin cancer prevention.<Reference refidx="1"/> The review identified 21 trials on promoting protective behaviors in 27 publications with 20,561 participants. Protective behaviors included use of protective clothing to limit UV radiation exposure, sun-avoidance behaviors, and use of sunscreen. Interventions included physician counseling, tailored mailings and texts, educational presentations, and interactive web programs involving patients and families. Five of six trials in children found that interventions reduced parent-reported composite sun protection scores at 3 months to 3 years.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/>  Six of twelve trials in adults also showed that interventions resulted in a reduced patient-reported composite sun protection score, with the greatest change being increased use of sunscreen.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/></Para><Para id="_249">The trials did not show a consistent change in sunburns for children or adults. In the three trials of children that assessed changes in sunburn frequency (n = 2,508),<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/>  only one trial showed a reduction in nonsevere burns, but no change in severe burns.<Reference refidx="15"/> In the six trials of adults that assessed changes in sunburn frequency (n = 3,959),<Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/>  only one trial showed a slight reduction in red or painful burns at 3 months.<Reference refidx="17"/>  There were no changes reported in any trial showing reductions in skin cancer (keratinocyte carcinoma or melanoma) or skin cancer precursors (nevi or actinic keratosis).</Para><Para id="_250">While direct evidence is lacking, the USPSTF linked the evidence demonstrating that behavioral counseling interventions promote sun protective practices with the epidemiological data on UV exposure and skin cancer prevalence. This led to a recommendation for counseling children, adolescents, and young adults aged 6 months to 24 years and adults older than 24 years with fair skin on protective practices to reduce skin cancer.<Reference refidx="23"/> </Para></SummarySection><SummarySection id="_175"><Title>Topical Treatment to Prevent Skin Cancer—Sunscreen</Title><Para id="_310">Sunscreen use has been shown to decrease the rate of developing new actinic keratoses <Reference refidx="24"/> and to increase the remission rate of existing lesions.<Reference refidx="25"/>  Another trial found no difference in keratinocyte cancers in daily versus discretionary sunscreen users.<Reference refidx="26"/>    An 8-year observational posttrial follow-up showed reductions in both squamous cancers <Reference refidx="27"/> and melanomas <Reference refidx="28"/> associated with sunscreen use, but the confidence intervals (CIs) were very wide, and the participation outside the initial trial introduced uncertainty.</Para><Para id="_255">A meta-analysis of 18 studies that explored the association between melanoma risk and previous sunscreen use illustrated widely differing study qualities and suggested little or no association.<Reference refidx="29"/> A systematic review of the association between sunscreen use and the development of melanocytic nevi in children reported similar issues with study quality and heterogeneity, hindering conclusive assessments. However, of the 15 studies that met inclusion criteria, 12 found either an increased incidence or no association.<Reference refidx="30"/></Para></SummarySection><SummarySection id="_293"><Title>Systemic Medications to Prevent Skin Cancer</Title><SummarySection id="_256"><Title>Nonsteroidal anti-inflammatory drugs (NSAIDS)</Title><Para id="_257">A randomized controlled trial (RCT) included 240 people at high risk of skin cancer (each with 10–40 actinic keratoses and a history of previous skin cancer) who were given celecoxib 200 mg twice daily or a placebo for 9 months. The trial found no difference in the incidence of actinic keratosis, but a post hoc analysis revealed a statistically significant difference in the mean number of keratinocyte carcinomas per patient (rate ratio, 0.43; 95% CI, 0.24–0.75; absolute difference, 0.2 lesions per patient).<Reference refidx="31"/> A meta-analysis of nine studies (five case-control, three cohort, and one intervention) reported a small reduction in squamous cell carcinoma (SCC) risk associated with the use of nonaspirin NSAIDs (relative risk [RR], 0.85; 95% CI, 0.78–0.94), with the effect seen particularly in those with previous actinic skin tumors.<Reference refidx="32"/></Para><Para id="_258">NSAIDs are associated with known adverse cardiovascular effects, gastrointestinal bleeding, and kidney damage.<Reference refidx="33"/></Para></SummarySection><SummarySection id="_259"><Title>Nicotinamide (vitamin B3)</Title><Para id="_260">The effect of nicotinamide on the development of new actinic keratosis lesions has been studied with inadequate evidence for efficacy, even in higher-risk populations. Studies include a clinical trial of patients with four or fewer actinic keratosis lesions at baseline (Oral Nicotinamide to Reduce Actinic Cancer [ONTRAC]) <Reference refidx="34"/> and a trial of immunosuppressed organ-transplant recipients (Oral Nicotinamide to Reduce Actinic Cancer after Transplant [ONTRANS]).<Reference refidx="35"/>  The ONTRAC trial showed a lower rate of new lesions while individuals received treatment, but not during the 6-month postintervention follow-up period.<Reference refidx="36"/> The ONTRANS trial was impacted by slow recruitment and was stopped early but showed no efficacy in the limited sample size.</Para></SummarySection><SummarySection id="_261"><Title>Isotretinoin and related systemic retinoids such as acitretin</Title><Para id="_262">Retinoids are vitamin A derivatives that are available in topical and oral preparations.   Oral retinoids have been studied in high-risk populations, such as those with a history of multiple nonmelanoma skin cancers, genetic disorders such as xeroderma pigmentosum, transplant recipients, and those exposed to high cumulative levels of psoralen plus UV A (PUVA) therapy.<Reference refidx="37"/><Reference refidx="38"/><Reference refidx="39"/><Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/> However, side effects of oral retinoids, including hypertriglyceridemia and hepatic toxicity, are significant.</Para><Para id="_263">Topical tretinoin 0.1% cream was compared with a control for 1.5 to 5.5 years in an RCT. No difference was found in the proportions of patients who developed SCC or basal cell carcinoma (BCC) or actinic keratosis.<Reference refidx="44"/></Para></SummarySection><SummarySection id="_264"><Title>Selenium</Title><Para id="_265">A multicenter, double-blind, randomized, placebo-controlled trial included 1,312
patients with a history of BCC or SCC and a mean
follow-up of 6.4 years. The study showed that 200 µg of selenium (in brewer’s yeast tablets)
did not have a statistically significant effect on the primary end point of
BCC development, but selenium instead increased the risk of SCC and total keratinocyte carcinomas (unadjusted RR, 1.27; 95% CI, 1.11–1.45).<Reference refidx="45"/><Reference refidx="46"/></Para></SummarySection><SummarySection id="_271"><Title>Beta carotene</Title><Para id="_272">In the Physicians’ Health Study, 21,884 male physicians with no reported history of BCC or SCC were randomly assigned to take 50 mg doses of daily oral beta carotene versus placebo in a 2 × 2 factorial trial of beta carotene and aspirin.<Reference refidx="47"/>   After 12 years, there was no difference in incidence of either BCC or SCC between the beta carotene and placebo groups.    Similar findings were noted in 10 years and 14 years of follow-up among the participants in the Nurses’ Health Study and the Health Professionals Follow-up Study.<Reference refidx="48"/>  Reanalysis of data from these two cohorts after an additional 16 years of follow-up noted higher intake of some carotenoids was associated with a modest reduction in SCC risk.<Reference refidx="49"/> Data on the use of sun protection behaviors were not available, and as participants with higher intake tended to have higher levels of physical activity, lower smoking, and alcohol consumption, it is possible that there was a confounding effect of sun protection behaviors. RCTs
of long-term treatment with beta carotene in individuals previously treated for
keratinocyte carcinoma also showed no benefit in preventing the occurrence of new keratinocyte carcinomas.<Reference refidx="26"/><Reference refidx="50"/></Para><Para id="_273">Several RCTs show that beta carotene supplementation can increase cardiovascular disease mortality and increase the risk of lung cancer.<Reference refidx="51"/><Reference refidx="52"/></Para></SummarySection><SummarySection id="_274"><Title>Alpha-difluoromethylornithine (DFMO)</Title><Para id="_275">An RCT of oral DFMO (500 mg/m<Superscript>2</Superscript>/day) versus placebo for up to 5 years (n = 250 participants) showed no difference in the number of new keratinocyte carcinomas.<Reference refidx="53"/> A subset analysis showed a difference in BCC events favoring the DFMO group (0.28 vs. 0.40 per year; <Emphasis>P</Emphasis> = .03) but no difference in SCC rates. However, the DFMO group experienced greater hearing loss than the placebo group (4 dB vs. 2 dB, <Emphasis>P</Emphasis> = .003), resulting in a higher study drug discontinuation rate (10.8% vs. 4.5%). </Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="29558557">Henrikson NB, Morrison CC, Blasi PR, et al.: Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319 (11): 1143-1157, 2018.</Citation><Citation idx="2" PMID="16376977">Crane LA, Deas A, Mokrohisky ST, et al.: A randomized intervention study of sun protection promotion in well-child care. Prev Med 42 (3): 162-70, 2006.</Citation><Citation idx="3" PMID="20218761">Glasser A, Shaheen M, Glenn BA, et al.: The sun sense study: an intervention to improve sun protection in children. Am J Health Behav 34 (4): 500-10, 2010 Jul-Aug.</Citation><Citation idx="4" PMID="17283299">Norman GJ, Adams MA, Calfas KJ, et al.: A randomized trial of a multicomponent intervention for adolescent sun protection behaviors. Arch Pediatr Adolesc Med 161 (2): 146-52, 2007.</Citation><Citation idx="5" PMID="22992358">Crane LA, Asdigian NL, Barón AE, et al.: Mailed intervention to promote sun protection of children: a randomized controlled trial. Am J Prev Med 43 (4): 399-410, 2012.</Citation><Citation idx="6" PMID="23806094">Glanz K, Steffen AD, Schoenfeld E, et al.: Randomized trial of tailored skin cancer prevention for children: the Project SCAPE family study. J Health Commun 18 (11): 1368-83, 2013.</Citation><Citation idx="7" PMID="25524612">Youl PH, Soyer HP, Baade PD, et al.: Can skin cancer prevention and early detection be improved via mobile phone text messaging? A randomised, attention control trial. Prev Med 71: 50-6, 2015.</Citation><Citation idx="8" PMID="15896835">Prochaska JO, Velicer WF, Redding C, et al.: Stage-based expert systems to guide a population of primary care patients to quit smoking, eat healthier, prevent skin cancer, and receive regular mammograms. Prev Med 41 (2): 406-16, 2005.</Citation><Citation idx="9" PMID="20167900">Glanz K, Schoenfeld ER, Steffen A: A randomized trial of tailored skin cancer prevention messages for adults: Project SCAPE. Am J Public Health 100 (4): 735-41, 2010.</Citation><Citation idx="10" PMID="21422325">Janda M, Neale RE, Youl P, et al.: Impact of a video-based intervention to improve the prevalence of skin self-examination in men 50 years or older: the randomized skin awareness trial. Arch Dermatol 147 (7): 799-806, 2011.</Citation><Citation idx="11" PMID="24499249">Walton AE, Janda M, Youl PH, et al.: Uptake of skin self-examination and clinical examination behavior by outdoor workers. Arch Environ Occup Health 69 (4): 214-22, 2014.</Citation><Citation idx="12" PMID="16580059">Glazebrook C, Garrud P, Avery A, et al.: Impact of a multimedia intervention "Skinsafe" on patients' knowledge and protective behaviors. Prev Med 42 (6): 449-54, 2006.</Citation><Citation idx="13" PMID="26810358">Heckman CJ, Darlow SD, Ritterband LM, et al.: Efficacy of an Intervention to Alter Skin Cancer Risk Behaviors in Young Adults. Am J Prev Med 51 (1): 1-11, 2016.</Citation><Citation idx="14" PMID="17500622">Mahler HI, Kulik JA, Gerrard M, et al.: Long-term effects of appearance-based interventions on sun protection behaviors. Health Psychol 26 (3): 350-60, 2007.</Citation><Citation idx="15" PMID="17533068">Weinstock MA, Risica PM, Martin RA, et al.: Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial. Am J Prev Med 32 (6): 517-24, 2007.</Citation><Citation idx="16" PMID="22539073">Lin SW, Wheeler DC, Park Y, et al.: Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer 131 (6): E1015-23, 2012.</Citation><Citation idx="17" PMID="22016471">Lazovich D, Vogel RI, Berwick M, et al.: Melanoma risk in relation to use of sunscreen or other sun protection methods. Cancer Epidemiol Biomarkers Prev 20 (12): 2583-93, 2011.</Citation><Citation idx="18" PMID="24408678">Veierød MB, Couto E, Lund E, et al.: Host characteristics, sun exposure, indoor tanning and risk of squamous cell carcinoma of the skin. Int J Cancer 135 (2): 413-22, 2014.</Citation><Citation idx="19" PMID="25062934">Ferrucci LM, Vogel RI, Cartmel B, et al.: Indoor tanning in businesses and homes and risk of melanoma and nonmelanoma skin cancer in 2 US case-control studies. J Am Acad Dermatol 71 (5): 882-7, 2014.</Citation><Citation idx="20" PMID="27639256">Weinstock MA, Lott JP, Wang Q, et al.: Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. Br J Dermatol 176 (4): 949-954, 2017.</Citation><Citation idx="21" PMID="25730254">Committee opinion no. 626: the transition from pediatric to adult health care: preventive care for young women aged 18-26 years. Obstet Gynecol 125 (3): 752-754, 2015.</Citation><Citation idx="22">American Academy of Dermatology: Skin Cancer. Washington, DC: American Academy of Dermatology Association, 2020. <ExternalRef xref="https://www.aad.org/media/stats-skin-cancer">Available online</ExternalRef>. Last accessed April 8, 2025.</Citation><Citation idx="23" PMID="29558558">Grossman DC, Curry SJ, Owens DK, et al.: Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319 (11): 1134-1142, 2018.</Citation><Citation idx="24" PMID="7857113">Naylor MF, Boyd A, Smith DW, et al.: High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 131 (2): 170-5, 1995.</Citation><Citation idx="25" PMID="8377777" MedlineID="93390561">Thompson SC, Jolley D, Marks R: Reduction of solar keratoses by regular sunscreen use. N Engl J Med 329 (16): 1147-51, 1993.</Citation><Citation idx="26" PMID="10475183">Green A, Williams G, Neale R, et al.: Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354 (9180): 723-9, 1999.</Citation><Citation idx="27" PMID="17132769">van der Pols JC, Williams GM, Pandeya N, et al.: Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 15 (12): 2546-8, 2006.</Citation><Citation idx="28" PMID="21135266">Green AC, Williams GM, Logan V, et al.: Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 29 (3): 257-63, 2011.</Citation><Citation idx="29" PMID="14678916">Dennis LK, Beane Freeman LE, VanBeek MJ: Sunscreen use and the risk for melanoma: a quantitative review. Ann Intern Med 139 (12): 966-78, 2003.</Citation><Citation idx="30" PMID="22994908">de Maleissye MF, Beauchet A, Saiag P, et al.: Sunscreen use and melanocytic nevi in children: a systematic review. Pediatr Dermatol 30 (1): 51-9, 2013 Jan-Feb.</Citation><Citation idx="31" PMID="21115882">Elmets CA, Viner JL, Pentland AP, et al.: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 102 (24): 1835-44, 2010.</Citation><Citation idx="32" PMID="15713944">Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (11): 1071-80, 2005.</Citation><Citation idx="33" PMID="23726390">Bhala N, Emberson J, Merhi A, et al.: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (9894): 769-79, 2013.</Citation><Citation idx="34" PMID="22297641">Surjana D, Halliday GM, Martin AJ, et al.: Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132 (5): 1497-500, 2012.</Citation><Citation idx="35" PMID="36856616">Allen NC, Martin AJ, Snaidr VA, et al.: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med 388 (9): 804-812, 2023.</Citation><Citation idx="36" PMID="26488693">Chen AC, Martin AJ, Choy B, et al.: A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 373 (17): 1618-26, 2015.</Citation><Citation idx="37" PMID="14512910">Nijsten TE, Stern RS: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 49 (4): 644-50, 2003.</Citation><Citation idx="38" PMID="11340613">DiGiovanna JJ: Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 36 (5): 564-7, 2001.</Citation><Citation idx="39" PMID="9367069">Moon TE, Levine N, Cartmel B, et al.: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 6 (11): 949-56, 1997.</Citation><Citation idx="40" PMID="3287161" MedlineID="88232826">Kraemer KH, DiGiovanna JJ, Moshell AN, et al.: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318 (25): 1633-7, 1988.</Citation><Citation idx="41" PMID="1293159">Kraemer KH, DiGiovanna JJ, Peck GL: Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 19 (11): 715-8, 1992.</Citation><Citation idx="42" PMID="10233316">McKenna DB, Murphy GM: Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 140 (4): 656-60, 1999.</Citation><Citation idx="43" PMID="15837863">Harwood CA, Leedham-Green M, Leigh IM, et al.: Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 141 (4): 456-64, 2005.</Citation><Citation idx="44" PMID="22318383">Weinstock MA, Bingham SF, Digiovanna JJ, et al.: Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 132 (6): 1583-90, 2012.</Citation><Citation idx="45" PMID="8971064" MedlineID="97126140">Clark LC, Combs GF, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (24): 1957-63, 1996.</Citation><Citation idx="46" PMID="14519754" MedlineID="22882342">Duffield-Lillico AJ, Slate EH, Reid ME, et al.: Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95 (19): 1477-81, 2003.</Citation><Citation idx="47" PMID="10677093">Frieling UM, Schaumberg DA, Kupper TS, et al.: A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol 136 (2): 179-84, 2000.</Citation><Citation idx="48" PMID="12455062">Fung TT, Spiegelman D, Egan KM, et al.: Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. Int J Cancer 103 (1): 110-5, 2003.</Citation><Citation idx="49" PMID="31365038">Kim J, Park MK, Li WQ, et al.: Association of Vitamin A Intake With Cutaneous Squamous Cell Carcinoma Risk in the United States. JAMA Dermatol 155 (11): 1260-1268, 2019.</Citation><Citation idx="50" PMID="2202901" MedlineID="90363259">Greenberg ER, Baron JA, Stukel TA, et al.: A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 323 (12): 789-95, 1990.</Citation><Citation idx="51" PMID="8602180" MedlineID="96185731">Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (18): 1150-5, 1996.</Citation><Citation idx="52" PMID="8127329" MedlineID="94173292">The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330 (15): 1029-35, 1994.</Citation><Citation idx="53" PMID="20051371">Bailey HH, Kim K, Verma AK, et al.: A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 3 (1): 35-47, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_30"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (04/08/2025)</Title><Para id="_32">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_320"><Strong><SummaryRef href="CDR0000062764#_107" url="/types/skin/hp/skin-prevention-pdq">Incidence and Mortality of Skin Cancer</SummaryRef></Strong></Para><Para id="_321">Added American Cancer Society as <SummaryRef href="CDR0000062764#_109" url="/types/skin/hp/skin-prevention-pdq">reference 1</SummaryRef>.</Para><Para id="_322">Updated <SummaryRef href="CDR0000062764#_110" url="/types/skin/hp/skin-prevention-pdq">statistics</SummaryRef> with estimated new cases and deaths of melanoma for 2025.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062764#_AboutThis_1" url="/types/skin/hp/skin-prevention-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about skin cancer prevention. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <SummaryRef href="CDR0000304747" url="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Screening and Prevention Editorial Board. PDQ Skin Cancer Prevention. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/skin/hp/skin-prevention-pdq">https://www.cancer.gov/types/skin/hp/skin-prevention-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389494]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-04-08</DateLastModified></Summary>
